Want to see PMI full AI Analyst Report?
PMI Stock Chart & Stats
$0.09
-$0.03(-27.06%)
At close: 4:00 PM EDT
$0.09
-$0.03(-27.06%)
Day’s Range― - ―
52-Week Range$3.08 - $684.00
Previous CloseN/A
Volume6.87M
Average Volume (3M)24.26M
Market Cap
$7.04M
Enterprise Value$80.57
Total Cash (Recent Filing)$121.00K
Total Debt (Recent Filing)$3.27M
Price to Earnings (P/E)―
Beta-2.08
Next Earnings
Sep 21, 2026EPS Estimate
-1.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.41
Shares Outstanding2,053,919
10 Day Avg. Volume60,852,368
30 Day Avg. Volume24,263,915
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)34.04
Price to Sales (P/S)26.11
P/FCF Ratio-8.23
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market-leading FDA/Health Canada Approval And Installed BaseBeing the sole FDA- and Health Canada-approved total artificial heart with a >2,100-install base provides durable clinical and commercial moats. Regulatory approval, clinical adoption, and global footprint create high barriers to entry, recurring replacement/driver demand and long-term referral channels for patients and hospitals.
Sustained Revenue Growth And Improving Gross MarginsRapid top-line growth and a move to positive gross margins signal improving product-market fit and operational leverage. If management sustains higher U.S. sales, in‑house manufacturing and driver tech progress, these trends support durable margin expansion and a clearer path to scaled commercial profitability over the medium term.
Material Reduction In Funded Debt And Improved LeverageA sizeable reduction in total debt materially lowers interest burden and near-term refinancing risk, improving financial flexibility. Combined with recent equity raises, the lower leverage provides a more durable runway for product development and commercialization while reducing immediate solvency pressures.
Bears Say
Heavy And Persistent Operating Cash BurnLarge negative operating and free cash flows indicate the company is structurally cash‑consumptive and will remain dependent on external financing until operations scale or costs fall. This creates ongoing dilution risk, constrains investment choices for R&D and commercialization, and elevates execution risk over the medium term.
Negative Equity And Exchange Listing Compliance RiskA stockholders' deficit undermines financial flexibility and has triggered NYSE notices and a compliance process. The need to regain equity compliance within a set window forces capital raises or profit improvements, which structurally pressures governance, increases dilution risk, and could threaten listing status if not resolved.
Very Large Operating And Net Losses With Negative MarginsExtremely negative operating and net margins show the business is far from break-even: fixed costs, R&D and SG&A outpace revenue. Even with revenue acceleration, such deep losses imply a long horizon to sustainable profitability and continued dependence on financing, amplifying strategic and execution vulnerabilities.
Picard Medical, Inc. News
PMI FAQ
What was Picard Medical, Inc.’s price range in the past 12 months?
Picard Medical, Inc. lowest stock price was $3.08 and its highest was $684.00 in the past 12 months.
What is Picard Medical, Inc.’s market cap?
Picard Medical, Inc.’s market cap is $7.04M.
When is Picard Medical, Inc.’s upcoming earnings report date?
Picard Medical, Inc.’s upcoming earnings report date is Sep 21, 2026 which is in 41 days.
How were Picard Medical, Inc.’s earnings last quarter?
Picard Medical, Inc. released its earnings results on May 21, 2026. The company reported -$5 earnings per share for the quarter, the consensus estimate of -$5 by $0.
Is Picard Medical, Inc. overvalued?
According to Wall Street analysts Picard Medical, Inc.’s price is currently Overvalued.
Does Picard Medical, Inc. pay dividends?
Picard Medical, Inc. does not currently pay dividends.
What is Picard Medical, Inc.’s EPS estimate?
Picard Medical, Inc.’s EPS estimate is -1.5.
How many shares outstanding does Picard Medical, Inc. have?
Picard Medical, Inc. has 2,053,919 shares outstanding.
What happened to Picard Medical, Inc.’s price movement after its last earnings report?
Picard Medical, Inc. reported an EPS of -$5 in its last earnings report, expectations of -$5. Following the earnings report the stock price went down -8.442%.
Which hedge fund is a major shareholder of Picard Medical, Inc.?
Currently, no hedge funds are holding shares in PMI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Picard Medical, Inc.
Picard Medical, Inc., through its associated companies, is dedicated to the entire process of medical device commercialization, from initial design and manufacturing to production, distribution, marketing, and sales. A key product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart specifically engineered to supplant a failing human heart in individuals afflicted with advanced cardiac disease. The firm's market presence extends across the United States, Europe, and other international regions. Established in 2021, Picard Medical maintains its primary operations in Tucson, Arizona, functioning as a direct subsidiary of Hunniwell Picard I, Llc.
PMI Company Deck
PMI Earnings Call
Q4 2026
0:00 / 0:00
PMI Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Aethlon Medical
―
―
Catheter Precision
―
Heart Test Laboratories, Inc.
―
Autonomix Medical, Inc.
―
Ownership Overview
―
Insiders
0.10% Mutual Funds
― Other Institutional Investors
97.45% Public Companies and
Individual Investors